Ultragenyx Pharmaceutical Inc
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
RARE$15.43-0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
During the three months ended June 30, 2024, the following directors and Section 16 officers adopteda Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Dennis HuangEVP, Chief Technical Operations Officer, Gene Therapy Research & Development | May 7, 2024 | Up to 75,000 shares, all of which are shares to be acquired upon the exercise of stock options | July 15, 2025 |
| John PinionChief Quality Operations Officer and EVP, Translational Sciences | May 7, 2024 | Up to 109,730 shares, 107,800 of which are shares to be acquired upon the exercise of stock options | May 7, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.